Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a wound dressing is provided comprising a scaffold coated with a biologically active composition comprising a lipoic acid derivative. In a further embodiment, a system is provided for treating a tissue site of a patient, the system comprising a reduced-pressure source to supply reduced pressure, a manifold to distribute reduced pressure to a tissue site and a scaffold coated with a biologically active composition comprising a lipoic acid derivative. Methods for producing such a system and scaffold are also disclosed.
1. A reduced-pressure therapy system for treating a tissue site, comprising:
a manifold at least partially coated with a composition comprising a gelatin substrate, a lipoic acid derivative, and a chelating agent, wherein the composition reduces excessive matrix metalloprotease activity, and wherein the lipoic acid derivative has the structure:
wherein n 1 and n 2 are, independently, C 1 -C 10 alkyl; and R 1 is H, C 1 -C 10 alkyl, C 6 -C 14 aryl, an alkyl ammonium or a protonated amino acid;
a drape adapted to provide a sealed space around the manifold and the tissue site; and
a reduced-pressure source configured to deliver reduced pressure to the sealed space.
2. The system of claim 1 , further comprising a scaffold adapted to be positioned between the manifold and the tissue site, wherein the scaffold has a plurality of passages.
3. The system of claim 2 , wherein the scaffold comprises polyurethane or collagen.
4. The system of claim 2 , further comprising a release layer adapted to be positioned between the scaffold and the manifold.
5. The system of claim 1 , further comprising an interface for fluidly coupling the reduced-pressure source to the sealed space.
6. The system of claim 1 , wherein the lipoic acid derivative comprises alpha-lipoic acid or sodium lipoate.
7. The system of claim 1 , wherein the chelating agent comprises ethylenediaminetetraacetic acid.
8. The system of claim 1 , wherein the composition further comprises an antimicrobial agent, a growth factor, or a preservative.
9. The system of claim 8 , wherein the antimicrobial agent is non-ionic silver, polyhexamethylene biguanide, chlorhexidine, benzalconium chloride, or triclosan.
10. The system of claim 1 , wherein the composition further preserves granulation tissue.
11. The system of claim 1 , wherein the composition is formulated for time-controlled release of the lipoic acid derivative.
12. The system of claim 1 , wherein the composition comprises 0.1% to 25% w/w gelatin substrate.
13. The system of claim 1 , wherein the composition comprises a bloom value of between about 150-300 g.
14. The system of claim 1 , wherein the composition comprises a bloom value of between about 200-250 g.
15. The system of claim 1 , wherein the composition comprises a bloom value of about 225 g.